Research & Development
Clinical Oncology Programs
Cyclacel Pharmaceuticals has built a deep pipeline of small molecule drug candidates, principally through internal discovery efforts, that target the cell cycle to treat human cancers and other serious disorders. Cyclacel Pharmaceuticals' pipeline currently includes three clinical-stage compounds, sapacitabine (CYC682), seliciclib (CYC202) and CYC116; and a large portfolio of development candidates.
Cyclacel Pharmaceuticals' internal efforts have been focused on developing drugs for oncology indications. The company partners with other top-tier biotechnology and pharmaceutical companies to develop drugs for non-oncology indications.
Clinical Drug Pipeline